{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-057722","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.810834+00:00","generated_at":"2026-06-15T08:43:45.741234+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Iovance Q1 net loss $107.4M, cash $632.7M; BLA submitted for lifileucel","bullets":["Q1 net loss $107.4M ($0.50 per share) vs loss of $91.6M ($0.58) in Q1 2022.","Cash $632.7M as of Mar 31, 2023, incl $260.1M from ATM facility; expected to fund into H2 2024.","Completed rolling BLA submission for lifileucel in post-anti-PD-1 advanced melanoma in March 2023.","Plans to acquire Proleukin; closing expected Q2 2023.","Commercial launch preparations for lifileucel on track for 2023; iCTC capacity for 2,000+ patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-057722","json":"https://secwatch.observer/filing/0001104659-23-057722.json","markdown":"https://secwatch.observer/filing/0001104659-23-057722.md","text":"https://secwatch.observer/filing/0001104659-23-057722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923057722/0001104659-23-057722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923057722/tm2315161d1_8kseq1.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:43:45.741234+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6c13665b2ef3b873b3972678ce1a38c27b34a39f","claim":"IOVANCE BIOTHERAPEUTICS, INC. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 9, 2023, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023 and an update on recent developments.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923057722/0001104659-23-057722-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}